BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11896423)

  • 1. Is there an upper age limit for bone marrow transplantation?
    Popplewell LL; Forman SJ
    Bone Marrow Transplant; 2002 Feb; 29(4):277-84. PubMed ID: 11896423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update.
    Vigorito AC; Marques Júnior JF; Aranha FJ; Oliveira GB; Miranda EC; De Souza CA
    Haematologica; 2001 Jun; 86(6):665-6. PubMed ID: 11418381
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft engineering.
    Noga SJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):15-21. PubMed ID: 10877046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hematopoietic stem cell transplantation].
    Sato N
    Rinsho Byori; 2001 Mar; Suppl 115():103-10. PubMed ID: 11391926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of bone marrow and stem cell transplantation.
    Johns A
    J Intraven Nurs; 1998; 21(6):356-60. PubMed ID: 10392101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic PBPC transplantation: an effect on incidence and distribution of chronic graft-versus-host disease without long-term survival benefit?
    Snowden JA; Nivison-Smith I; Atkinson K; Fay K; Concannon A; Dodds A; Milliken S; Biggs J
    Bone Marrow Transplant; 2000 Jan; 25(1):119-20. PubMed ID: 10654027
    [No Abstract]   [Full Text] [Related]  

  • 15. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
    Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
    Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow.
    Elfenbein GJ; Sackstein R
    Exp Hematol; 2004 Apr; 32(4):327-39. PubMed ID: 15050742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
    Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.